Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.

Trial Details

NCT ID
NCT07501117
Phase
PHASE1
Sponsor
Inge Marie Svane
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Nivolumab & Ipilimumab
Locations (sample)
  • Herlev, Herlev, Denmark|55.72366,12.43998

Key Eligibility Criteria

  • Age ≥ 18 ≤ 80
  • The patient is able to read and understand Danish.
  • Primary, localized and treatment-naive uveal melanoma planned for enucleation (high risk/T3-T4) and available for transvitreal biopsies. The initia…
  • ECOG performance status of 0 or 1 (appendix 2)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →